# Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

> **NCT01740531** · PHASE3 · COMPLETED · sponsor: **Cerus Corporation** · enrollment: 86 (actual)

## Conditions studied

- Thalassemia Major

## Interventions

- **BIOLOGICAL:** S-303 Treated Red Blood Cells (RBCs)
- **BIOLOGICAL:** Conventional, untreated Red Blood Cells

## Key facts

- **NCT ID:** NCT01740531
- **Lead sponsor:** Cerus Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2017-12-21
- **Final completion:** 2017-12-31
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01740531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01740531, "Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01740531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*